Jiyeon Si
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Jiyeon Si has a total of 72 co-authors. Here are the top co-authors by number of shared publications:
- Jeroen Raes
Laboratory of Molecular Bacteriology, Rega Institute, KU Leuven, Leuven, Belgium
3 shared publications Christoph Leitner
Department of Internal Medicine, Hospital of Bruneck, Bruneck, Italy
2 shared publicationsGregorio Rungger
Department of Neurology, Hospital of Bruneck, Bruneck, Italy
2 shared publications- Herbert Tilg
Department of Internal Medicine I, Gastroenterology, Hepatology, Endocrinology and Metabolism, Medizinische Universitat Innsbruck, Innsbruck, Austria
2 shared publications - Johann Willeit
Department of Neurology, Medical University Innsbruck , Innsbruck
2 shared publications Leen Rymenans
Department of Microbiology and Immunology, Rega Institute for Medical Research, Leuven, Belgium
2 shared publications
Latest Publications
- Open Access
Stage-dependent gut microbiome and functional signatures across the liver disease spectrum: an integrative multicohort study
Background: The gut-liver axis plays a critical role in liver disease progression; however, how gut microbial ecology and function vary across disease stages remains unclear. Objective: To define stage-specific microbial and functional signatures and evaluate their diagnostic potential. Design: We analysed faecal samples from 1168 individuals spanning healthy controls, fatty liver, hepatitis, cirrhosis and hepatocellular carcinoma by 16S rRNA sequencing, with a subset (n=141) profiled by shotgun metagenomics. To increase statistical power and enable external validation, 2376 publicly available metagenomic datasets, including 734 liver-related, were integrated. Machine learning-based multicohort analysis was used to identify microbial biomarkers, assess risk factors and classify disease stages. Results: Microbial diversity declined and a low-richness enterotype expanded with disease severity. Machine learning revealed a discordance in hepatitis, which lacked taxonomic markers but was defined by a conserved functional signature of biosynthetic upregulation. In contrast, advanced stages featured consistent markers like Ligilactobacillus and Veillonella , with strain-level evidence confirming oral-gut transmission. Functional profiling delineated a metabolic continuum from anabolic precursor synthesis in hepatitis to virulence factor production in cirrhosis and putrefactive metabolism in carcinoma. Comparative analysis confirmed that these signatures were distinct from those in non-liver metabolic and oncologic disorders. Importantly, the expansion of oral-derived Veillonella spp and the low-richness enterotype were significantly associated with increased mortality. Conclusion: This large-scale study delineates stage-dependent ecological and functional remodelling of the gut microbiome across liver diseases. These findings highlight the potential of microbiome-based markers for non-invasive diagnosis and prognostic risk stratification in liver diseases.
Open AccessStage-dependent gut microbiome and functional signatures across the liver disease spectrum: an integrative multicohort study
Background: The gut-liver axis plays a critical role in liver disease progression; however, how gut microbial ecology and function vary across disease stages remains unclear. Objective: To define stage-specific microbial and functional signatures and evaluate their diagnostic potential. Design: We analysed faecal samples from 1168 individuals spanning healthy controls, fatty liver, hepatitis, cirrhosis and hepatocellular carcinoma by 16S rRNA sequencing, with a subset (n=141) profiled by shotgun metagenomics. To increase statistical power and enable external validation, 2376 publicly available metagenomic datasets, including 734 liver-related, were integrated. Machine learning-based multicohort analysis was used to identify microbial biomarkers, assess risk factors and classify disease stages. Results: Microbial diversity declined and a low-richness enterotype expanded with disease severity. Machine learning revealed a discordance in hepatitis, which lacked taxonomic markers but was defined by a conserved functional signature of biosynthetic upregulation. In contrast, advanced stages featured consistent markers like Ligilactobacillus and Veillonella , with strain-level evidence confirming oral-gut transmission. Functional profiling delineated a metabolic continuum from anabolic precursor synthesis in hepatitis to virulence factor production in cirrhosis and putrefactive metabolism in carcinoma. Comparative analysis confirmed that these signatures were distinct from those in non-liver metabolic and oncologic disorders. Importantly, the expansion of oral-derived Veillonella spp and the low-richness enterotype were significantly associated with increased mortality. Conclusion: This large-scale study delineates stage-dependent ecological and functional remodelling of the gut microbiome across liver diseases. These findings highlight the potential of microbiome-based markers for non-invasive diagnosis and prognostic risk stratification in liver diseases.
- Open Access
- 14 October 2022
- Published by Springer Nature in Nature Aging
- Vol. 2 (10) , 885-895
Long-term life history predicts current gut microbiome in a population-based cohort study
Extensive scientific and clinical microbiome studies have explored contemporary variation and dynamics of the gut microbiome in human health and disease1–3, yet the role of long-term life history effects has been underinvestigated. Here, we analyzed the current, quantitative microbiome composition in the older adult Bruneck Study cohort (Italians, Bruneck,n = 304 (male, 154; female, 150); age 65–98 years) with extensive clinical, demographic, lifestyle and nutritional data collected over the past 26 years4. Multivariate analysis of historical variables indicated that medication history, historical physical activity, past dietary habits and specific past laboratory blood parameters explain a significant fraction of current quantitative microbiome variation in older adults, enlarging the explanatory power of contemporary covariates by 33.4%. Prediction of current enterotype by a combination of past and contemporary host variables revealed good levels of predictability (area under the curve (AUC), 0.78–0.83), withPrevotellaand dysbioticBacteroides2 being the best predicted enterotypes. These findings demonstrate long-term life history effects on the microbiota and provide insights into lifestyle variables and their role in maintaining a healthy gut microbiota in later life.
- 14 October 2022
- Published by Springer Nature in Nature Aging
- Vol. 2 (10) , 885-895
Open AccessLong-term life history predicts current gut microbiome in a population-based cohort study
Extensive scientific and clinical microbiome studies have explored contemporary variation and dynamics of the gut microbiome in human health and disease1–3, yet the role of long-term life history effects has been underinvestigated. Here, we analyzed the current, quantitative microbiome composition in the older adult Bruneck Study cohort (Italians, Bruneck,n = 304 (male, 154; female, 150); age 65–98 years) with extensive clinical, demographic, lifestyle and nutritional data collected over the past 26 years4. Multivariate analysis of historical variables indicated that medication history, historical physical activity, past dietary habits and specific past laboratory blood parameters explain a significant fraction of current quantitative microbiome variation in older adults, enlarging the explanatory power of contemporary covariates by 33.4%. Prediction of current enterotype by a combination of past and contemporary host variables revealed good levels of predictability (area under the curve (AUC), 0.78–0.83), withPrevotellaand dysbioticBacteroides2 being the best predicted enterotypes. These findings demonstrate long-term life history effects on the microbiota and provide insights into lifestyle variables and their role in maintaining a healthy gut microbiota in later life.
- Open Access
- 25 May 2022
- Published by Taylor & Francis in Gut Microbes
- Vol. 14 (1) , 2078619
Revisiting the role of Akkermansia muciniphila as a therapeutic bacterium
Despite a short history since its first isolation, Akkermansia muciniphila has been extensively studied in relation to its effects on human metabolism. A recent human intervention study also demonstrated that the bacterium is safe to use for therapeutic purposes. The best-known effects of A. muciniphila in human health and disease relate to its ability to strengthen gut integrity, modulate insulin resistance, and protect the host from metabolic inflammation. A further molecular mechanism, induction of GLP-1 secretion through ICAM-2 receptor, was recently discovered with the identification of a new bacterial protein produced by A. muciniphila. However, other studies have suggested a detrimental role for A. muciniphila in specific host immune settings. Here, we evaluate the molecular, mechanistic effects of A. muciniphila in host health and suggest some of the missing links to be connected before the organism should be considered as a next-generation biotherapeutic agent.
- 25 May 2022
- Published by Taylor & Francis in Gut Microbes
- Vol. 14 (1) , 2078619
Open AccessRevisiting the role of Akkermansia muciniphila as a therapeutic bacterium
Despite a short history since its first isolation, Akkermansia muciniphila has been extensively studied in relation to its effects on human metabolism. A recent human intervention study also demonstrated that the bacterium is safe to use for therapeutic purposes. The best-known effects of A. muciniphila in human health and disease relate to its ability to strengthen gut integrity, modulate insulin resistance, and protect the host from metabolic inflammation. A further molecular mechanism, induction of GLP-1 secretion through ICAM-2 receptor, was recently discovered with the identification of a new bacterial protein produced by A. muciniphila. However, other studies have suggested a detrimental role for A. muciniphila in specific host immune settings. Here, we evaluate the molecular, mechanistic effects of A. muciniphila in host health and suggest some of the missing links to be connected before the organism should be considered as a next-generation biotherapeutic agent.
- Open Access
- 25 January 2021
- Published by Springer Nature in Research Square
Long-term life history predicts current elderly gut microbiome
Extensive scientific and clinical microbiome studies have explored contemporary variation and dynamics of the gut microbiome in human health and disease1–4, yet the role of long-term life-history effects is underinvestigated. Here, we analyzed the current microbiome composition in the elderly Bruneck Study cohort (n = 304; age 65–98) with extensive clinical, demographic, lifestyle, and nutritional data collected over the past 26 years. Combined analysis with the Flemish Gut Flora Project cohort (FGFP; n = 2,215; age 18–85) showed community richness increasing during aging linked to increased observation of low-abundance bacteria. Multivariate analysis of historical variables indicated that medication history, historical physical activity, past dietary habits, and specific past laboratory parameters explain a significant fraction of current elderly quantitative microbiome variation, enlarging the explanatory power of contemporary covariates by 33.4%. Prediction of current enterotype by past host variables revealed good levels of predictability (AUC > 0.7) for the Prevotella and dysbiotic Bacteroides 2 enterotypes with information from up to 15 years past. These findings demonstrate long-term life history effects on the microbiota and provide first insights into lifestyle variables and their role in maintaining a healthy gut microbiota in later life.
- 25 January 2021
- Published by Springer Nature in Research Square
Open AccessLong-term life history predicts current elderly gut microbiome
Extensive scientific and clinical microbiome studies have explored contemporary variation and dynamics of the gut microbiome in human health and disease1–4, yet the role of long-term life-history effects is underinvestigated. Here, we analyzed the current microbiome composition in the elderly Bruneck Study cohort (n = 304; age 65–98) with extensive clinical, demographic, lifestyle, and nutritional data collected over the past 26 years. Combined analysis with the Flemish Gut Flora Project cohort (FGFP; n = 2,215; age 18–85) showed community richness increasing during aging linked to increased observation of low-abundance bacteria. Multivariate analysis of historical variables indicated that medication history, historical physical activity, past dietary habits, and specific past laboratory parameters explain a significant fraction of current elderly quantitative microbiome variation, enlarging the explanatory power of contemporary covariates by 33.4%. Prediction of current enterotype by past host variables revealed good levels of predictability (AUC > 0.7) for the Prevotella and dysbiotic Bacteroides 2 enterotypes with information from up to 15 years past. These findings demonstrate long-term life history effects on the microbiota and provide first insights into lifestyle variables and their role in maintaining a healthy gut microbiota in later life.
- Top Cited PapersOpen Access
- 13 January 2021
- Published by Springer Nature in Nature
- Vol. 590 (7844) , 151-156
Local immune response to food antigens drives meal-induced abdominal pain
Up to 20% of people worldwide develop gastrointestinal symptoms following a meal1, leading to decreased quality of life, substantial morbidity and high medical costs. Although the interest of both the scientific and lay communities in this issue has increased markedly in recent years, with the worldwide introduction of gluten-free and other diets, the underlying mechanisms of food-induced abdominal complaints remain largely unknown. Here we show that a bacterial infection and bacterial toxins can trigger an immune response that leads to the production of dietary-antigen-specific IgE antibodies in mice, which are limited to the intestine. Following subsequent oral ingestion of the respective dietary antigen, an IgE- and mast-cell-dependent mechanism induced increased visceral pain. This aberrant pain signalling resulted from histamine receptor H1-mediated sensitization of visceral afferents. Moreover, injection of food antigens (gluten, wheat, soy and milk) into the rectosigmoid mucosa of patients with irritable bowel syndrome induced local oedema and mast cell activation. Our results identify and characterize a peripheral mechanism that underlies food-induced abdominal pain, thereby creating new possibilities for the treatment of irritable bowel syndrome and related abdominal pain disorders.
- 13 January 2021
- Published by Springer Nature in Nature
- Vol. 590 (7844) , 151-156
Top Cited PapersOpen AccessLocal immune response to food antigens drives meal-induced abdominal pain
Up to 20% of people worldwide develop gastrointestinal symptoms following a meal1, leading to decreased quality of life, substantial morbidity and high medical costs. Although the interest of both the scientific and lay communities in this issue has increased markedly in recent years, with the worldwide introduction of gluten-free and other diets, the underlying mechanisms of food-induced abdominal complaints remain largely unknown. Here we show that a bacterial infection and bacterial toxins can trigger an immune response that leads to the production of dietary-antigen-specific IgE antibodies in mice, which are limited to the intestine. Following subsequent oral ingestion of the respective dietary antigen, an IgE- and mast-cell-dependent mechanism induced increased visceral pain. This aberrant pain signalling resulted from histamine receptor H1-mediated sensitization of visceral afferents. Moreover, injection of food antigens (gluten, wheat, soy and milk) into the rectosigmoid mucosa of patients with irritable bowel syndrome induced local oedema and mast cell activation. Our results identify and characterize a peripheral mechanism that underlies food-induced abdominal pain, thereby creating new possibilities for the treatment of irritable bowel syndrome and related abdominal pain disorders.